Microbot Medical Inc. — 2015 Q2 filing summary
Filing identity: The supplied filing is StemCells, Inc.’s Form 10-Q for the quarter ended June 30, 2015, not a Microbot Medical filing. The summary below reflects the filing provided.
Business context and reporting period
StemCells was a clinical-stage biopharmaceutical company developing human neural stem-cell therapies, principally for chronic spinal cord injury and dry age-related macular degeneration (AMD). Financial statements are unaudited; comparisons are with the three and six months ended June 30, 2014.
Financial results and liquidity
| Metric | Q2 2015 | First half 2015 |
|---|---|---|
| Revenue | $30,131 | $51,128 |
| Operating expenses | $9.30 million | $18.28 million |
| Operating loss | $9.27 million | $18.23 million |
| Net loss | $8.46 million | $17.81 million |
| Net loss per share | $0.09 | $0.22 |
- First-half operating cash use was $16.48 million, versus $14.28 million a year earlier; investing cash use was $0.41 million.
- Cash and cash equivalents were $29.93 million at June 30, up from $24.99 million at year-end 2014, mainly reflecting approximately $24.94 million of net proceeds from an April equity offering.
- Current assets were $31.03 million and current liabilities $9.62 million. Loan payable, net of discount, totaled $12.38 million ($3.47 million current); reported total liabilities were $21.72 million.
- Revenue was immaterial relative to research and development spending; conventional profit margins are not informative for this loss-making development-stage business.
Changes versus the prior comparable period
- First-half revenue rose 9% to $51,128, while total operating expenses increased 23% to $18.28 million. Research and development expense rose 29% to $13.53 million, reflecting staffing, stock compensation, clinical studies and supplies.
- First-half net loss narrowed to $17.81 million from $19.74 million, principally because the prior-year period included a $3.98 million warrant-liability revaluation expense; the 2015 period instead recorded $0.64 million of warrant-liability revaluation income.
- Shares outstanding increased substantially after the April-May 2015 offering. At June 30, 108.1 million common shares were outstanding, compared with 68.7 million at December 31, 2014; the filing also reported 53.9 million warrants outstanding at June 30.
Outlook, risks and unusual items
- Management expected substantial future operating losses and said significant additional capital would be needed. It warned that unavailable or unacceptable financing could force delays, reductions or termination of development programs and could jeopardize the ability to meet obligations.
- Clinical update: the six-patient first cohort of the Phase II Pathway spinal-cord-injury study was completed in April, and enrollment in its 40-patient second cohort began in June. The first patient in the Phase II Radiant dry-AMD study was transplanted in July 2015, after quarter-end.
- Prior thoracic spinal-cord-injury results showed reported sensory gains in some patients, but the filing describes these as preliminary. In the earlier dry-AMD study, prospective analyses suggested slower geographic-atrophy progression in most treated eyes, while a separate post-hoc analysis did not show the same trend; further analysis was ongoing.
- The CIRM Alzheimer’s preclinical funding agreement was terminated after program findings failed to meet continuation criteria. StemCells repaid approximately $679,000; approximately $8.92 million of principal and $0.24 million of accrued interest were described as forgiven, but derecognition remained subject to required legal-release conditions.
- In July 2015, a court dismissed the company’s Neuralstem patent case with prejudice for lack of standing. The company said other patent families and proprietary expertise were unaffected and did not consider the decision material.
- The 2015 offering included warrants and triggered anti-dilution repricing of older Series A warrants from $1.40 to approximately $0.70 per share. The older warrants were recorded as a liability, so fair-value changes affect reported earnings without representing operating cash flow.
- Contractual cash obligations totaled $18.88 million, including $15.24 million of operating-lease payments. Management gave no meaningful product-commercialization timetable and did not expect profitability in the next several years.
Important facts for investors to verify
- Confirm the issuer and reporting period: the provided document is StemCells, Inc.’s 2015 Q2 10-Q, not a Microbot Medical filing.
- Review subsequent cash use, financing needs, and the timing and terms of any new capital raises relative to the $29.93 million quarter-end cash balance.
- Track clinical-trial enrollment, safety and efficacy results, and the unresolved dry-AMD analysis; reported findings remain preliminary.
- Assess dilution from the 2015 offering, outstanding warrants and equity awards, including warrant exercise and anti-dilution terms.
- Check the status of the CIRM liability’s legal release and any subsequent developments in the dismissed patent litigation.